Skip to content

Transcranial Direct Current Stimulation for the Treatment of Deficits After Traumatic Brain Injury

Transcranial Direct Current Stimulation for the Treatment of Deficits After Traumatic Brain Injury

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02613936
Enrollment
40
Registered
2015-11-25
Start date
2015-09-30
Completion date
2022-07-31
Last updated
2023-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Executive Dysfunction, Post Concussive Symptoms, Traumatic Brain Injury

Keywords

traumatic brain injury, post concussive symptoms, depression, executive dysfunction, brain stimulation

Brief summary

Patients with mild-moderate traumatic brain injury (TBI) sustained between 3 months and 5 years ago with prolonged postconcussive symptoms will be recruited. On Day 1 of the study they will undergo neuropsychological (NP) testing. They will then undergo 10 days of Left dorsolateral prefrontal (DLPFC) anodal transcranial direct current stimulation (TDCS) (active or sham) combined with cognitive training. On day 10 NP testing will be obtained again. On Day 30, NP testing will be repeated a 3rd time. At 6 months and 1 year, quality of life, depression, and post concussive symptoms will be assessed.

Detailed description

Our long-term goal is to develop safe and effective treatments for symptoms of mild to moderate TBI (mmTBI) that restore patients to higher levels of functioning, decrease disability, and promote brain healing. The objective of this application is to investigate the use of transcranial direct current stimulation (tDCS) to treat symptoms of executive dysfunction and depression in patients with mmTBI. Our central hypotheses are (1) tDCS paired with relevant cognitive training facilitates improves executive function on National Institutes of Health (NIH)-approved neuropsychological measures, (2) tDCS reduces depression scores on NIH Common Data Elements for TBI, (3) that these improvements in emotion and cognition will be detectable up to one year after stimulation, and (4) certain clinical variables will reliably predict response to tDCS. These objectives were formulated based on our clinical experience with Dr. Ronald Yeo (project mentor) characterizing symptomatic patients with mmTBI in the post-acute setting and groundbreaking research led by Dr. Vincent Clark (project mentor) that has demonstrated robust increases in attention and learning with tDCS. Specific Aim 1: tDCS for executive dysfunction in mmTBI Experiments in this aim will test the hypothesis that in patients with mmTBI, left prefrontal anodal tDCS concurrent with cognitive training for ten consecutive weekdays will result in significantly more improvement in executive function compared to sham stimulation. Patients with cognitive complaints 3 months to 2 years after mmTBI will be recruited from local emergency departments and brain injury clinics. Aim 1.1: tDCS will be paired with computer-based cognitive training tasks of response inhibition, set shifting, and working memory, while executive function will be measured with the NIH Examiner battery before, immediately after, and one month after stimulation. Aim 1.2: Persistence of post-traumatic symptom reduction and quality of life improvement will be assessed with Common Data Elements instruments via telephone interview at 6 months and one year. Aim 1.3: Clinical predictors of tDCS response including injury severity, premorbid intelligence, and post-traumatic symptom burden will be determined with linear mixed-models analysis. Specific Aim 2: tDCS for depressive symptoms in mmTBI Experiments in this aim will test the hypothesis that left prefrontal anodal tDCS in patients with mmTBI will significantly reduce depressive symptoms compared to sham stimulation. Aim 2.1: Patients will be assessed for symptoms of depression via self-report instruments and clinician-administered scales from NIH Common Data Elements before, immediately after, and one month after the stimulation protocol. Aim 2.2: Persistence of antidepressant benefit will be assessed via telephone interview at 6 months and one year. Aim 2.3: clinical predictors of tDCS response such as injury severity, premorbid intelligence, and symptom burden will be determined.

Interventions

DEVICEAnodal tDCS

Anodal tDCS lowers neuronal membrane potentials, leading to increased probability of depolarization from incoming stimuli.

BEHAVIORALCognitive training

Cognitive training involves solving executive function tasks on a computer.

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
National Institute of General Medical Sciences (NIGMS)
CollaboratorNIH
University of New Mexico
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

1. aged 18-55 2. TBI with + loss of consciousness (LOC) less than 24 hours 3. injured between 3 months and 5 years ago 4. Glasgow Coma Score (GCS) between 9 and 15 upon emergency department (ED) admission 5. less than 1 week of post-traumatic amnesia (PTA) 6. 1 out of 4 cognitive symptoms on the Neurobehavioral Symptom Inventory (NSI)

Exclusion criteria

1. history of neurological disease or seizures 2. history of psychosis 3. history of recent substance dependence (past 2 years) 4. any skull defect 5. presence of any implanted electrical device 6. recent medical instability (within 3 weeks) 7. pregnancy 8. appointment of a legal representative.

Design outcomes

Primary

MeasureTime frameDescription
Examiner Score1 monthThe NIH Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research (EXAMINER) assesses executive function in four different domains, creating a composite score from all domains, ranging from -3.0 to 2.0 with higher scores indicating better outcome.

Countries

United States

Participant flow

Pre-assignment details

Study enrollment was concluded at 40 based on termination of funding.

Participants by arm

ArmCount
Active Anodal tDCS + Cognitive Training
In this arm, 40 patients with mmTBI will undergo 10 sessions of active tDCS x 30 minutes combined with simultaneous cognitive training on consecutive weekdays. Anodal tDCS: Anodal tDCS lowers neuronal membrane potentials, leading to increased probability of depolarization from incoming stimuli. Cognitive training: Cognitive training involves solving executive function tasks on a computer.
17
Placebo Anodal tDCS + Cognitive Training
In this arm, 40 patients with mmTBI will undergo 10 sessions of placebo tDCS x 30 minutes combined with simultaneous cognitive training on consecutive weekdays. Cognitive training: Cognitive training involves solving executive function tasks on a computer.
17
Total34

Baseline characteristics

CharacteristicActive Anodal tDCS + Cognitive TrainingPlacebo Anodal tDCS + Cognitive TrainingTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
17 Participants17 Participants34 Participants
Age, Continuous33.7 years
STANDARD_DEVIATION 12.3
35.8 years
STANDARD_DEVIATION 13.6
34.8 years
STANDARD_DEVIATION 13
Race and Ethnicity Not Collected0 Participants
Sex: Female, Male
Female
9 Participants7 Participants16 Participants
Sex: Female, Male
Male
8 Participants10 Participants18 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 170 / 17
other
Total, other adverse events
3 / 170 / 17
serious
Total, serious adverse events
0 / 170 / 17

Outcome results

Primary

Examiner Score

The NIH Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research (EXAMINER) assesses executive function in four different domains, creating a composite score from all domains, ranging from -3.0 to 2.0 with higher scores indicating better outcome.

Time frame: 1 month

ArmMeasureGroupValue (MEAN)Dispersion
Active Anodal tDCS + Cognitive TrainingExaminer ScoreBaseline0.617 score on a scaleStandard Deviation 0.677
Active Anodal tDCS + Cognitive TrainingExaminer ScoreEnd of Treatment0.865 score on a scaleStandard Deviation 0.677
Active Anodal tDCS + Cognitive TrainingExaminer Score1 month Visit1.037 score on a scaleStandard Deviation 0.677
Placebo Anodal tDCS + Cognitive TrainingExaminer ScoreBaseline0.907 score on a scaleStandard Deviation 0.659
Placebo Anodal tDCS + Cognitive TrainingExaminer ScoreEnd of Treatment1.155 score on a scaleStandard Deviation 0.669
Placebo Anodal tDCS + Cognitive TrainingExaminer Score1 month Visit1.26 score on a scaleStandard Deviation 0.659

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026